MedPath

Maraviroc

Generic Name
Maraviroc
Brand Names
Celsentri, Selzentry
Drug Type
Small Molecule
Chemical Formula
C29H41F2N5O
CAS Number
376348-65-1
Unique Ingredient Identifier
MD6P741W8A
Background

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.

Indication

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions
CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV

Phase 2
Completed
Conditions
HIV-1-infection
Hepatic Steatosis
Interventions
First Posted Date
2017-04-26
Last Posted Date
2021-11-04
Lead Sponsor
University College, London
Target Recruit Count
90
Registration Number
NCT03129113
Locations
🇬🇧

King's College Hospital, London, United Kingdom

🇬🇧

Royal Free Hospital, London, United Kingdom

🇬🇧

Royal London Hospital, London, United Kingdom

and more 3 locations

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Not Applicable
Completed
Conditions
HIV
Chronic Infection
Interventions
Biological: Dendritic Cell Vaccine
Drug: Sirtuin Histone deacetylase inhibitor
First Posted Date
2016-11-11
Last Posted Date
2020-07-28
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
30
Registration Number
NCT02961829
Locations
🇧🇷

CCDI, Sao Paulo, SP, Brazil

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

Not Applicable
Completed
Conditions
HIV Infection
Interventions
First Posted Date
2016-10-14
Last Posted Date
2016-10-14
Lead Sponsor
Southern California Institute for Research and Education
Target Recruit Count
25
Registration Number
NCT02934022
Locations
🇺🇸

VA Long Beach Healthcare System, Long Beach, California, United States

Maraviroc Efficacy for Hepatitis C

Phase 4
Completed
Conditions
Hepatitis C
Human Immunodeficiency Virus
Interventions
First Posted Date
2016-08-29
Last Posted Date
2024-05-01
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
10
Registration Number
NCT02881762
Locations
🇺🇸

Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, Maryland, United States

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

First Posted Date
2016-06-15
Last Posted Date
2016-06-15
Lead Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Target Recruit Count
40
Registration Number
NCT02799888
Locations
🇨🇳

Department of Hematopoietic Stem Cell Transplantation, Beijing, Beijing, China

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

Phase 1
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2016-05-19
Last Posted Date
2022-01-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
47
Registration Number
NCT02778204
Locations
🇺🇸

Usc La Nichd Crs, Los Angeles, California, United States

🇺🇸

St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States

🇰🇪

Kenya Medical Research Institute / Walter Reed Project Clinical Research Center, Kericho CRS, Kericho, Kenya

and more 6 locations

Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

Phase 2
Completed
Conditions
HIV Infections
Kidney Diseases
Interventions
Drug: Placebo
First Posted Date
2016-04-18
Last Posted Date
2023-08-21
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
97
Registration Number
NCT02741323
Locations
🇺🇸

UCLA HIVTR-CCR5 Non-Network CRS, Los Angeles, California, United States

🇺🇸

UAB HIVTR-CCR5 Non-Network CRS, Birmingham, Alabama, United States

🇺🇸

UCSF HIVTR-CCR5 Non-network CRS, San Francisco, California, United States

and more 7 locations

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Darunavir/cobicistat (Part 2)
First Posted Date
2015-12-09
Last Posted Date
2017-04-17
Lead Sponsor
ViiV Healthcare
Target Recruit Count
47
Registration Number
NCT02625207
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

Phase 4
Completed
Conditions
HIV Infections
Interventions
Drug: Placebo for maraviroc (MVC)
Drug: Placebo for dolutegravir (DTG)
First Posted Date
2015-08-11
Last Posted Date
2022-04-22
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
191
Registration Number
NCT02519777
Locations
🇺🇸

UCSD Antiviral Research Center CRS, San Diego, California, United States

🇺🇸

Northwestern University CRS, Chicago, Illinois, United States

🇺🇸

Johns Hopkins University CRS, Baltimore, Maryland, United States

and more 27 locations

Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication

Early Phase 1
Terminated
Conditions
HIV-1 Infection
Interventions
First Posted Date
2015-07-01
Last Posted Date
2015-12-18
Lead Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Target Recruit Count
7
Registration Number
NCT02486510
Locations
🇪🇸

Hospital Universitario Ramon Y Cajal, Madrid, Spain

🇪🇸

Hospital Universitario La Paz, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy